^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MK-3120
i
Other names: MK-3120, SKB410, SKB-410, SKB 410, MK 3120, MK3120
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Merck (MSD), Sichuan Kelun Pharma
Drug class:
Topoisomerase I inhibitor, Nectin-4-targeted antibody-drug conjugate
Related drugs:
11d
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) (clinicaltrials.gov)
P1/2, N=270, Recruiting, Merck Sharp & Dohme LLC | N=180 --> 270 | Trial completion date: Jan 2028 --> Mar 2031 | Trial primary completion date: Jan 2028 --> Oct 2028
Enrollment change • Trial completion date • Trial primary completion date
|
MK-3120
17d
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) (clinicaltrials.gov)
P1/2, N=55, Not yet recruiting, Merck Sharp & Dohme LLC
New P1/2 trial
|
Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • MK-3120
17d
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) (clinicaltrials.gov)
P1/2, N=45, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
Enrollment open
|
MK-3120
1m
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) (clinicaltrials.gov)
P1/2, N=45, Not yet recruiting, Merck Sharp & Dohme LLC
New P1/2 trial
|
MK-3120
4ms
SKB410 for Injection in Solid Tumors (clinicaltrials.gov)
P1, N=54, Active, not recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | N=276 --> 54 | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Dec 2025
Enrollment change • Trial completion date • Trial primary completion date
|
MK-3120
5ms
KEYMAKER-U04 substudy 04A: A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) (clinicaltrials.gov)
P1/2, N=48, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2027 --> May 2028 | Trial primary completion date: Oct 2027 --> May 2028
Trial completion date • Trial primary completion date
|
Keytruda (pembrolizumab) • zilovertamab vedotin (MK-2140) • MK-3120
8ms
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) (clinicaltrials.gov)
P1/2, N=180, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
Enrollment open
|
MK-3120
10ms
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) (clinicaltrials.gov)
P1/2, N=180, Not yet recruiting, Merck Sharp & Dohme LLC
New P1/2 trial
|
MK-3120
11ms
SKB410 for Injection in Solid Tumors (clinicaltrials.gov)
P1, N=276, Active, not recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Recruiting --> Active, not recruiting
Enrollment closed
|
MK-3120
over1year
SKB410 for Injection in Solid Tumors (clinicaltrials.gov)
P1, N=276, Recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
MK-3120
over2years
SKB410 for Injection in Solid Tumors (clinicaltrials.gov)
P1, N=276, Not yet recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
New P1 trial • Metastases
|
MK-3120
Share via
